Fay JW - Search Results

1

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Chari A, et al. Among authors: fay jw. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. Blood. 2017. PMID: 28637662 Free PMC article. Clinical Trial.

2

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.

Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL. Chari A, et al. Among authors: fay jw. Cancer. 2016 Nov 15;122(21):3327-3335. doi: 10.1002/cncr.30174. Epub 2016 Jul 19. Cancer. 2016. PMID: 27433944 Free PMC article. Clinical Trial.

3

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.

Pan D, Kaufman JL, Htut M, Agrawal M, Mazumder A, Cornell RF, Zonder JA, Fay JW, Modiano MR, Moshier EL, Rush SA, Tunquist BJ, Chari A. Pan D, et al. Among authors: fay jw. Cancer Med. 2022 Jan;11(2):358-370. doi: 10.1002/cam4.4451. Epub 2021 Dec 17. Cancer Med. 2022. PMID: 34921527 Free PMC article. Clinical Trial.

4

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.

5

Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation.

Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, et al. Phillips GL, et al. Among authors: fay jw. Blood. 1989 Jun;73(8):2086-92. Blood. 1989. PMID: 2659100 Free article.

6

FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.

Fay JW, Wingard JR, Antin JH, Collins RH, Piñeiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ. Fay JW, et al. Blood. 1996 Apr 15;87(8):3514-9. Blood. 1996. PMID: 8605372 Free article. Clinical Trial.

7

Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement.

Tong AW, Lee JC, Fay JW, Stone MJ. Tong AW, et al. Among authors: fay jw. Blood. 1987 Nov;70(5):1482-9. Blood. 1987. PMID: 3663943 Free article.

8

The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.

Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, et al. Phillips GL, et al. Among authors: fay jw. Blood. 1990 Feb 15;75(4):831-8. Blood. 1990. PMID: 2302456 Free article.

9

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. Stone MJ, et al. Among authors: fay jw. Blood. 1996 Aug 15;88(4):1188-97. Blood. 1996. PMID: 8695836 Free article. Clinical Trial.

10

Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.

Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C, Li S, Saracino G, Tadic-Ovcina M, Fay J. Agura E, et al. Oncologist. 2011;16(2):197-206. doi: 10.1634/theoncologist.2010-0220. Epub 2011 Jan 27. Oncologist. 2011. PMID: 21273514 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters